The estimated Net Worth of Mark Froimson is at least $726 millier dollars as of 12 August 2024. Mark Froimson owns over 1,400 units of Pacira BioSciences Inc stock worth over $188,149 and over the last 7 years he sold PCRX stock worth over $112,409. In addition, he makes $424,946 as Independent Director at Pacira BioSciences Inc.
Mark has made over 4 trades of the Pacira BioSciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,400 units of PCRX stock worth $16,212 on 12 August 2024.
The largest trade he's ever made was buying 1,400 units of Pacira BioSciences Inc stock on 12 August 2024 worth over $16,212. On average, Mark trades about 231 units every 183 days since 2017. As of 12 August 2024 he still owns at least 14,473 units of Pacira BioSciences Inc stock.
You can see the complete history of Mark Froimson stock trades at the bottom of the page.
Dr. Mark I. Froimson M.D. serves as Independent Director of the Company. Dr. Froimson is currently a Principal at Riverside Health Advisors, a consulting company that provides strategic advice and services to health care executive leaders. Dr. Froimson served as the President of the American Association of Hip and Knee Surgeons from March 2017 to March 2018. Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Prior to his executive leadership position at Trinity Health, Dr. Froimson was President and Chief Executive Officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions, including President of the professional staff, Vice Chair of the Orthopedic and Rheumatologic Institute, and member of the board of governors and board of trustees. Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University.
As the Independent Director of Pacira BioSciences Inc, the total compensation of Mark Froimson at Pacira BioSciences Inc is $424,946. There are 17 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Mark Froimson is 59, he's been the Independent Director of Pacira BioSciences Inc since 2018. There are 9 older and 12 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon et Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: